EpiCypher releases multiomic single-molecule genomics platform
EpiCypher has launched CUTANA® Fiber-seq, a multiomic genomics platform that simultaneously captures genomic and epigenomic information through single long-read sequencing assays. The Durham, North Carolina-based company announced the technology on 3 September 2025, marking a significant development in molecular genomics capabilities.
The platform addresses fundamental limitations in current genomic analysis by providing base-pair resolution of chromatin features along individual DNA molecules. Unlike conventional ATAC-seq methodologies, Fiber-seq delivers precise detection of transcription factor footprints and protein-DNA interactions that regulate gene expression.
Technical methodology and workflow
The Fiber-seq workflow employs nuclei treatment with Hia5 methyltransferase, which deposits 6mA marks at accessible DNA regions. Chromatin fibres are subsequently extracted and analysed using long-read sequencing platforms from PacBio® or Oxford Nanopore Technologies®. This process enables direct detection of both Hia5-incorporated 6mA modifications and underlying DNA sequences.
The methodology generates singlemolecule, multiomic readouts that integrate genetic information, endogenous DNA methylation, and chromatin accessibility across continuous DNA molecules. This approach provides unprecedented resolution of DNA sequence and chromatin features along individual molecules.
“Fiber-seq gives an unprecedented view of the genome – not just the sequence, but the epigenomic states of individual DNA molecules,” said Dr Michael-Christopher Keogh, chief scientific officer at EpiCypher. “This offers a new lens into biology and disease, with transformative implications for fundamental research and translational science.”
Commercial offerings and applications
EpiCypher has released the CUTANA Hia5 for Fiber-seq enzyme as an initial commercial product, enabling researchers to implement the optimised protocol in laboratory settings. The company also provides Early Access CUTANA Fiber-seq Assay Services, extending their established automated CUTANA CUT&RUN platform capabilities.
The technology addresses applications
across multiple research domains, including basic and translational research for mapping genetic and epigenetic features, drug discovery and development for identifying therapeutic targets, and clinical research for precision medicine applications. A recent Nature Genetics publication demonstrated Fiber-seq’s capabilities in diagnosing rare diseases by uncovering genetic drivers of rare disorders.
“We are thrilled to bring epigenomics to the cutting-edge of long read sequencing technology,” said Martis Cowles, chief business officer at EpiCypher. “CUTANA Fiber-seq is the gateway to a powerful new era of single-molecule multiomics that will advance research and precision medicine in ways that were simply not possible using current short read workflows.”
For more information, visit: https://epicypher.com
Digital issue: Please click here for more information
